IL17A (rs2275913 G>A) and IL17F (rs2397084 T>C) Gene Polymorphisms: Relation to Psoriasis Risk and Response to Methotrexate.

Abstract

Background The relation of IL17 polymorphisms to psoriasis risk and response to methotrexate has not been previously studied in Egyptians. Objectives To study the relation of IL17A (rs2275913 G>A) and IL17F (rs2397084 T>C) polymorphisms to psoriasis risk and assess their predictive role as regards response to methotrexate.Patients & Methods IL17A (rs 2275913) and IL17F (rs 2397084) polymorphisms were evaluated in 100 healthy subjects and 100 patients with chronic plaque psoriasis by real time-PCR. Patients were given methotrexate weekly intramuscularly (0.6mg/kg) for 12 weeks. Results IL17F TT genotype was more frequent in patients (87%) than controls (68%), while TC genotype was more frequent in controls (32%) than patients (13%). TT genotype was associated with increased risk of psoriasis whereas the TC allele was associated with a decreased risk. There was no significant difference regarding IL17A GG, GA and AA genotype frequencies between patients and controls. PASI ≥75% was achieved in 22 patients (73.3%) with the TT genotype and 8 patients (26.7%) with TC genotype (p=0.019). Conclusion IL17F (rs2397084 T>C) TT genotype could be considered a susceptibility marker in Egyptian patients. Psoriatic patients with TT genotype and T allele of IL17F (rs2397084 T>C) are likely to show a better response to methotrexate.

Interleukin-4 (C-589T) and Interleukin-17 (-197 G>A) Gene Polymorphisms in Psoriasis patients in Thi-Qar province south of Iraq

“…Also, the study of Kim et al, 2017 did not show any association between the IL-17 polymorphism (-197 G>A) and psoriasis in the Korean population. In the study of Hamza et al, (2021), it was found that the G allele was 79% and 80.5% in the healthy and patients, respectively, while the A allele was 21% and 19.5% in the healthy and patients, respectively with non-significant difference between patients and healthy subjects (p. value=0.759). On the other hand, Mohamed et al, (2020) revealed an association of the IL-17(-G197A) polymorphism with several autoimmune and inflammatory diseases such as inflammatory bowel disease and psoriasis.…”

Genetic Influence on Treatment Response in Psoriasis: New Insights into Personalized Medicine

“…Regarding annexin A6 (ANxA6), a susceptibility factor for psoriasis, the rs11960458-TT/CT genotype was significantly more likely to be unresponsive to MTX in both short (12 weeks) and long-term (1 year) treatment, whereas the rs960709 and rs13168551 polymorphisms were only associated with short-term efficacy [51]. Other polymorphisms have been associated with better (IL-17F rs2397084-T allele [52]; TNIP1 rs10036748-TT genotype [53]) or worse responses (GNMT rs10948059-TT genotype; DNMT3b rs2424913-CT/TT genotype [49]) to methotrexate, although studies with larger sample sizes and on different populations will be needed to consolidate these data.…”